According to Fortune Business Insights, the global real world evidence solutions market size was valued at USD 20.03 billion in 2025 and is projected to grow from USD 22.3 billion in 2026 to USD 65.42 billion by 2034, exhibiting a CAGR of 14.40% during the forecast period. North America dominated the real world evidence solutions market with a market share of 42.11% in 2025. Moreover, the U.S. real-world evidence solutions market size is projected to grow significantly, reaching an estimated value of USD 17.79 billion by 2032, driven by increasing usage of real-world evidence solutions by biopharmaceutical companies.
The market is gaining prominence as pharmaceutical companies, biotechnology organizations, healthcare providers, and regulatory authorities increasingly utilize real-world data to support clinical research, drug development, and healthcare decision-making. Real world evidence solutions involve the collection, integration, and analysis of healthcare information obtained from routine clinical practice and other real-world sources. These solutions help stakeholders understand treatment effectiveness, evaluate patient outcomes, monitor drug safety, and identify potential opportunities for improving healthcare delivery. The growing emphasis on evidence-based medicine and the increasing complexity of clinical research are strengthening demand for advanced real-world evidence platforms and analytical services.
Continue reading for more details:
https://www.fortunebusinessinsights.com/real-world-evidence-solutions-market-107676
The real world evidence solutions market is segmented by component, application, end user, and other relevant categories. Based on component, the market is divided into services and datasets. Services include consulting, data integration, analytics, and other specialized support activities. The services segment benefits from increasing demand for professional expertise in managing complex healthcare information and generating meaningful insights. Organizations increasingly depend on specialized service providers to integrate information from multiple sources, conduct statistical analysis, and develop evidence-based research strategies. The datasets segment is also important because comprehensive and reliable healthcare information forms the foundation of real-world evidence generation. These datasets may include electronic health records, medical claims, clinical data, patient registries, and other healthcare information sources.
Based on application, the market covers drug development and approvals, medical device development and approvals, post-market surveillance, reimbursement and coverage decisions, and other applications. Drug development and approvals represent a significant application area as pharmaceutical companies increasingly utilize real-world evidence to complement conventional clinical trial findings. These solutions help researchers evaluate treatment effectiveness across broader patient populations and understand how medicines perform under routine healthcare conditions. Post-market surveillance is another important application because it enables companies and regulatory authorities to monitor product safety and identify potential adverse events after commercialization. Real-world evidence also supports medical device manufacturers in evaluating product performance and generating information required for regulatory and reimbursement decisions.
By end user, the market includes pharmaceutical and biotechnology companies, medical device manufacturers, healthcare providers, payers, and other organizations. Pharmaceutical and biotechnology companies represent a major customer group because they utilize real-world evidence to support clinical development, regulatory submissions, and product lifecycle management. Healthcare providers use these solutions to evaluate treatment outcomes and improve clinical decision-making. Payers and insurance organizations also utilize real-world evidence to assess treatment effectiveness, healthcare utilization, and reimbursement requirements.